上海復星醫藥(集團)股份有限公司 - H股 02196Stock Information

Stock Information · Old Rules
// Company Overview //
Stock Name上海復星醫藥(集團)股份有限公司 - H股
Stock Code02196
Company Full Name上海復星醫藥(集團)股份有限公司 - H股
Industry醫療保健
Principal Activities主要從事開發、制造和銷售醫藥產品和醫療設備、進出口醫療設備和提供相關及其他諮詢服務以及投資管理。
Listing Date2012-10-30
Listing Rules EraOld Rules
Listing Rules ChapterNo data
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市普陀區曹楊路510號9樓
Business Address (Hong Kong)No data
Place of IncorporationNo data
Listing MethodNo data
Listing BoardMain Board
Websitehttp://www.fosunpharma.com
Share Registrar卓佳證券登記有限公司
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo data
// Offering Information //
Prospectus Date2012-10-17
Offer PriceHK$ 11.80 / shares
Total Funds RaisedHK$ 778,800,000
// Valuation & Financials //
Market Cap (at Offer Price)HK$ 0
// First Day Performance
First Day CloseLoading...
First Day OpenHK$ 11.08
First Day Change-8.14%
First Day Volume54273500.0
First Day Turnover588861000.0
// Price Chart //
Loading...
// Use of Proceeds
Use of Proceeds1、約48%或1,806.9百萬港元將用于制藥、醫藥分銷及零售、醫藥健康、診斷產品及醫療器械領域的收購及合并; 2、約19%或715.2百萬港元將用于為現有的研發項目、擴充我們的研發團隊及收購新的研發項目融資; 3、約23%或865.8百萬港元將用于償還本集團的部分帶息負債的本金及利息; 4、約10%或376.4百萬港元將用于補充本集團的營運資金。
// Underwriting Syndicate //
联席保荐人 (4)
瑞银证券香港有限公司 中国国际金融香港证券有限公司 摩根大通证券(远东)有限公司 德意志银行香港分行
整体协调人 (4)
瑞银证券香港有限公司 中国国际金融香港证券有限公司 J.P. Morgan Securities (Asia Pacific) Limited 德意志银行香港分行
联席账簿管理人 (4)
瑞银证券香港有限公司 中国国际金融香港证券有限公司 J.P. Morgan Securities (Asia Pacific) Limited 德意志银行香港分行
联席牵头经办人 (4)
瑞银证券香港有限公司 中国国际金融香港证券有限公司 J.P. Morgan Securities (Asia Pacific) Limited 德意志银行香港分行
// Cornerstone Investors //
#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 The Prudential Insurance Company of America 387,624,100 HKD 9.77% 6 months 2013-04-30
2 国际金融公司 191,160,000 HKD 4.82% 6 months 2013-04-30
// Directors & Management //
Chairman陳玉卿,關曉暉
Company Secretary董曉嫻,陳秀玲
No director data available.
// Major Shareholders //
Major Shareholders & Holdings復星國際有限公司(60.70%);貝萊德(4.97%)
Disclaimer & Risk Warning

Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.

Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. Some data is supplemented from HKEX New Listing Reports ([HKEX]). All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.

Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.

Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.

Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.

Cibo — IPO & Market Data Analytics